DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Janet D. Dillione

Janet Dillione joined the Board of CorMedix in August 2015. Since November 2020, Janet has served as the Chief Executive Officer of Contact America, a nationally recognized leader in comprehensive telehealth and remote patient monitoring solutions. Prior to joining Contact America, she served as Chief Executive Officer of Bernoulli Enterprise, Inc since May 2014, a real-time connected healthcare information technology company. Previously, she was Executive Vice President and General Manager of the Healthcare Division at Nuance Communications, Inc., a leading provider of voice and language solutions for businesses and consumers around the world. From June 2000 to April 2010, Ms. Dillione held several senior level management positions at Siemens Medical Solutions, a global leader in medical imaging, laboratory diagnostics, and healthcare information technology, including President and CEO of the global healthcare IT division. Ms. Dillione has more than 25 years of experience leading global teams in the development and delivery of healthcare technology and services. In that time, she has acquired both financial expertise and significant senior management experience as a chief operating officer and executive officer that will allow her to be a valued addition to the company’s Board of Directors.